"Pharmaceutical Compositions of Spiro-Oxindole Compound for Topical Administration and Their Use as Therapeutic Agents" in Patent Application Approval Process. By a News Reporter-Staff News Editor at AIDS Weekly A patent application by the inventors Winters, Conrad Stewart; Yang, Meidong; Chen, Haigang, filed on October 11, 2016, was made availab
410 Medical, Inc., a medical device company focused on developing innovative technologies for the resuscitation of critically ill patients, today announced it will participate in the 2017 Advanced Pediatric Emergency Medicine Assembly being held April 25 27 in Las Vegas, Nevada. Organized by the American College of Emergency Physicians, PEM is
Gorm von Oettingen commented: "We are excited with the acquisition of Nexstim NBS and the unique diagnostic information it provides. We expect to be able to operate 25% more patients with central area tumours due to the ability of the Nexstim system to correctly plan these high-risk surgeries. " "NEXSTIM PLC Martin Jamieson, Chairman and CEO Furth
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of CaPre for the treatment of severe hypertriglyceridemia, today announced the granting of additional patents by the Taiwanese and Australian patent offices, further expanding the intellectual property position of CaPre.
Acerus Pharmaceuticals Corporation announced today that Tom Rossi, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the sixth annual Bloom Burton& Co. Healthcare Investor Conference. Rossi s address will take place at the Sheraton Centre Toronto Hotel on May 2, 2017 at 4:00 p.m. Eastern Time.
BALERNA, Switzerland& WERMELSKRICHEN, Germany APR Applied Pharma Research s.a., the Swiss independent developer of science driven and patent protected healthcare products, and ATG Allied Technologies Group, announce today the signature of a business partnership which allows to distribute and market the innovative active cleanser Nexodyn AOS.
Adamas Pharmaceuticals, Inc. today announced the presentation of two separate analyses of pooled data from the placebo-controlled Phase 3 clinical trials of ADS-5102 extended-release capsules in oral platform and poster presentation sessions at the 69 th American Academy of Neurology Annual Meeting in Boston. Adamas is excited to present this.
Addivant?, the world leading supplier of liquid phosphite antioxidants for plastics, announced today that its nonylphenol-free stabilizer, WESTON 705, has received formal approval from the US Food and Drug Administration for use in infant formula and human milk plastic packaging. This approval from the FDA for use in infant formula and human m
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Raymond S. Wysmierski as Director of Compliance, reporting to Carmen McCormick, Esq., Aerie s
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced that it will present data from an interim analysis of its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria, as well as preclinical data for additional indications and other opportunities, at today s Research and Development Day.
By a News Reporter-Staff News Editor at Pharma Business Week- Alere Inc., a global leader in rapid diagnostics, announced that its Alere? Reader, a diagnostic analyzer that can be used in both point-of-care and laboratory settings, has received 510 marketing clearance from the US Food and Drug Administration. This reformulated test card is the
By a News Reporter-Staff News Editor at Pharma Business Week- Allergan plc announced that it has been named a 2017 ENERGY STAR Partner of the Year- Sustained Excellence Award winner. Allergan will be recognized by the U.S. Environmental Protection Agency and the U.S. Department of Energy in Washington, D.C. on April 26, 2017. Allergan has been an
Amedica Corporation, an innovative medical device company that develops and commercializes silicon nitride, is pleased to announce it has been granted marketing clearance for its Valeo interbody fusion devices in Australia. The Valeo product line is made entirely of Amedica's proprietary medical grade silicon nitride ceramic an ideal material for
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3 clinical trial, HEART-FID. "Iron deficiency affects up to half of all heart failure patients and is associated with impaired exercise tolerance, and mortality in patients with or without anemia, 2" said Adrian F. Hernandez,
Amerigroup Tennessee, a statewide provider of Medicaid managed care services, today announced that it has been recognized by the National Committee for Quality Assurance, which awards distinction to organizations that meet or exceed its rigorous requirements for multicultural health care. As the demographics of America continues to shift to a mo
NEW YORK, NY/ ACCESSWIRE/ April 24, 2017/ Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on AmpliPhi Biosciences Corporation, a biopharmaceutical company engaged in the discovery, development, and commercializat
Anaconda BioMed, a pre-clinical stage medical device company focused on the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke, today announced it has appointed Creganna Medical to develop, test and manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical phases.
By a News Reporter-Staff News Editor at Clinical Trials Week ArQule, Inc. announced that it has received clearance from the U.S. Food and Drug Administration for the Investigational New Drug application to conduct a phase 1 clinical trial with ARQ 531 in patients with B-cell malignancies who are refractory to other therapeutic options.
Johannesburg Pharma giant Aspen says it welcomes a potential probe into alleged ant-competitive behaviour. This comes after the official opposition, the Democratic Alliance, last Wednesday said it would write to the Competition Commission and the Medicines Control Council to request that they investigate the market conduct of Aspen Pharmacare, t
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced promising clinical results from its Phase 1 b/2 003 trial assessing the safety and potential activity of Resolaris? in patients with early onset facioscapulohumeral muscular...
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced its participation as part of the Emerging Science Platform Session at the upcoming American Academy of Neurology 69 th Annual Meeting to be held April 22 28, 2017 in Boston, M
The new multi-disciplinary Oncology Precision Medicine Clinic will be located inside the Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center and will leverage molecular profiling technology to help patients explore additional treatment options that take into consideration the genetic characteristics of their tumors.
April 24 Sonavex, a medical device company in Baltimore, has raised $3 million to push the firm through the regulatory approval process for its device to detect blood clots. The round was led by Grey Sky Venture Partners with investments from CRCM Venture Capital, TEDCO, the Abell Foundation and individual private investors. The round includes $2
Release date- 21042017- Basel, Switzerland- Basilea Pharmaceutica Ltd. announced today that it has reached agreement with the US Food and Drug Administration on Special Protocol Assessments for its two planned phase 3 clinical studies of Basilea's antibiotic ceftobiprole. Achim Kaufhold, Basilea's Chief Medical Officer, said:' With the agreement on
-Will Create Highly Differentiated Medical Technology Company Focused on Delivering Innovative Healthcare Solutions to Improve Clinical and Economic Outcomes. FRANKLIN LAKES, NJ and MURRAY HILL, NJ- BD, a leading global medical technology company, and C. R. Bard, Inc., a medical technology leader in the fields of vascular, urology, oncology and sur